Adult-onset Still's disease secondary prevention

Adult-onset Still's disease
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Adult-onset Still’s Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Template:Adult-onset Still's disease On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Template:Adult-onset Still's disease All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Adult-onset Still's disease secondary prevention
CDC on Template:Adult-onset Still's disease
Template:Adult-onset Still's disease in the news
Blogs on Template:Adult-onset Still's disease
Risk calculators and risk factors for Template:Adult-onset Still's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.

Secondary Prevention

Secondary prevention of adult-onset Still's disease (AOSD) is aimed at preventing relapses of the disease. Tocilizumab may be used to prevent relapses associated with AOSD.